RNA at a glance
Atrium Therapeutics, Inc. (RNA, SEC CIK 2093101) filed a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Atrium Therapeutics, Inc. (RNA) shares worth $75.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $75.4M · +2 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly added risk: separation from Avidity increased costs, with standalone vendor charges potentially exceeding historical allocations
- Most materially updated risk: capital needs heightened after separation, with $72.3 million cash and $191.6 million short-term investments funding at least 12 months
- Regulatory risk: all programs remain discovery, preclinical, or clinical stage without completed pivotal trials or BLA submissions
- Operational risk: RNA delivery platform remains unproven for cardiac targets despite favorable neuromuscular results
- Financial risk: six-month net losses increased to $36.8 million from $20.3 million
AI summary of the RNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results
- Results are furnished rather than filed, limiting Exchange Act Section 18 liability and automatic incorporation into other filings
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $20.2M, or $1.18 per share, versus $12.9M, or $0.75, year-over-year
- FDA IND clearance enables ATR 1072’s Corventis Phase 1/2 trial, targeting approximately 37 PRKAG2 syndrome participants
Item 8.01: Other Events
- FDA IND clearance enables Atrium to begin the Corventis Phase 1/2 trial for ATR 1072
- Trial targets PRKAG2 syndrome, a rare genetic cardiac disorder
Item EX-99.1: Item EX-99.1
- FDA cleared ATR 1072’s IND, advancing Atrium’s first precision cardiology program into human trials
- Corventis Phase 1/2 trial targets PRKAG2’s underlying genetic driver, addressing a disease with no approved root-cause therapy
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results
- Results are furnished, not filed, limiting direct Exchange Act Section 18 liability and incorporation by reference
AI summaries of RNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RNA
Don't miss the next RNA filing
- Alerts as it files. A push when RNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RNA, by share count.
- Ask anything. An AI agent that reads every RNA filing and answers with sources.
RNA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Winslow Brendan R. | F | Sep 18, 2026 | 6,742 | $8.95 |
| Boyce Sarah | F | Sep 18, 2026 | 126,418 | $8.95 |
| Hughes Steven George | F | Sep 18, 2026 | 21,459 | $8.95 |
| Younis Husam | F | Sep 18, 2026 | 11,216 | $8.95 |
| Hoyos Rocio Martin | F | Sep 18, 2026 | 8,320 | $8.95 |
| Kenney Stephanie | F | Sep 18, 2026 | 2,375 | $8.95 |
| Flanagan W. Michael | F | Sep 18, 2026 | 22,812 | $8.95 |
| Gallagher Kathleen P. | F | Sep 18, 2026 | 11,632 | $8.95 |
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RNA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $75.4M |
| Q1 2026 | 21 | $71.2M |
- BlackRock+242.2K (+20%)
- Two Sigma Investments+166.9K (+93%)
- Vanguard Capital Management LLC+104.0K (+17%)
- Northern Trust+21.2K (+22%)
- State Street Corp+14.7K (+6%)
- Vanguard Portfolio Management LLC−243.2K (-71%)
- Morgan Stanley−123.1K (-75%)
- T. Rowe Price Group−80.2K (-5%)
- Citadel Advisors LLC−42.3K (-38%)
- Goldman Sachs Group−39.6K (-11%)
- AQR Capital Management+172.2K
- Franklin Resources+56.7K
- Renaissance Technologies LLC+15.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 44 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| SC 13G | Apr 8, 2026 | - | - | |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RNA SEC filings: frequently asked questions
Which institutions hold RNA stock?
As of June 30, 2026, the largest Atrium Therapeutics, Inc. (RNA) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($19.8 million), BlackRock ($19.5 million), Vanguard Capital Management LLC ($9.8 million), Two Sigma Investments ($4.6 million), Goldman Sachs Group ($4.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did RNA report in its latest 8-K?
Atrium Therapeutics, Inc. (RNA) filed an 8-K on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results.
What are the latest RNA SEC filings?
Atrium Therapeutics, Inc. (RNA) filed a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on September 22, 2026.
What is RNA's SEC CIK number?
Atrium Therapeutics, Inc. (RNA)'s SEC Central Index Key (CIK) is 2093101. EDGAR lists every RNA filing under that number.
Ask anything about RNA
The research agent reads RNA's filings, financials, insider trades and 13F holders, then answers with sources.